ntegration of the viral genome into host cell DNA is an obligate step in the HIV-1 life cycle. Integrase (IN), encoded by the pol gene, mediates this 2-step process. In the first step, termed 3Ј processing, IN cleaves a distal dinucleotide adjacent to a conserved CA located at each 3Ј end of the DNA copy of the viral genome. In the second step, termed strand transfer, IN covalently attaches the 3Ј processed viral DNA to the host genome (1).
I
ntegration of the viral genome into host cell DNA is an obligate step in the HIV-1 life cycle. Integrase (IN), encoded by the pol gene, mediates this 2-step process. In the first step, termed 3Ј processing, IN cleaves a distal dinucleotide adjacent to a conserved CA located at each 3Ј end of the DNA copy of the viral genome. In the second step, termed strand transfer, IN covalently attaches the 3Ј processed viral DNA to the host genome (1) .
IN consists of 3 functional domains: the N-terminal domain (NTD; residues 1-51) that contains a conserved ''HH-CC'' zincbinding motif, the catalytic core domain (CCD; residues 52-210) with the catalytic residues (D64, D116, and E152), and the Cterminal domain (CTD; residues 210-288) that contributes to DNA binding (2) . In solution, recombinant IN exists in a dynamic equilibrium between monomers, dimers, tetramers, and higherorder oligomers (3, 4) . Monomers are reportedly inactive in vitro, whereas dimers are able to catalyze 3Ј processing and integration of 1 viral end (4) (5) (6) (7) (8) (9) . Tetramers, which have also been isolated from human cells expressing HIV-1 IN (10), can catalyze integration of 2 viral DNA ends into target DNA (7, 11) , but the exact nature of the IN complex mediating 3Ј processing and strand transfer reactions remains to be determined. The integration step is an attractive drug target given its essential role in the viral life cycle and the lack of a cellular IN homologue. Strand transfer inhibitors appear to bind significantly better to IN when it is assembled on its DNA substrate than to IN alone (12) . To date there is only 1 structure of an inhibitor bound to IN (13) , and that is in the absence of DNA. The compound binds at the active site; however, it dimerizes across a crystallographic 2-fold axis and therefore might not be in its bioactive configuration.
Structure-based understanding of the mechanisms of the action of IN inhibitors and optimization of compounds as potential drugs targeting HIV-1 IN have been hampered by the inability to capture and crystallize IN-DNA complexes. Two key factors have contributed to this problem: first, the high salt concentration (Ϸ1 M NaCl) required to maintain full-length IN in solution interferes with DNA binding; second, IN has intrinsically low affinity for DNA. To overcome these 2 obstacles, we used disulfide cross-linking to generate soluble, catalytically-active, covalent IN-DNA complexes. A similar strategy, covalent disulfide cross-linking between HIV-1 reverse transcriptase (RT) and DNA, mediated crystallization of the RT-DNA complex (14) .
Previous cross-linking from cysteinal mutations in the CTD (6) and CCD (15) of IN with thiolated DNA substrates suggested that the CTD of 1 protomer of dimeric IN binds 1 end of viral DNA in trans with the CCD of the other protomer. However, while complexes were selected on the basis of IN-DNA cross-linking (6, 15) , enzymatic activities of the covalent IN-DNA complexes were not reported.
Here, we describe an IN cysteine mutant, IN Y143C , which is able to form IN-DNA complexes efficiently. The IN Y143C -DNA complexes form stable tetramers in solution, retain single-end strand transfer activity, show increased resistance to protease and nuclease digestion, and bind a strand transfer inhibitor. This IN-DNA complex can serve as an in vitro platform to identify and evolve strand transfer inhibitors of HIV integration and as a means of understanding the basis for a key part of the integration reaction.
Results

Selection of Most Stable Disulfide Cross-Linked IN-DNA Complexes.
To trap IN-DNA complexes with a viral DNA substrate bound in a biologically-relevant manner, we used available IN structures (16) (17) (18) to guide the selection of sites for the introduction of cysteine residues near the active site. We started with IN C56S/W131D/F185D/C280S/C65S , termed IN P . This protein incorporates 4 previously-described mutations designed to diminish surface hydrophobicity for improved solubility (termed IN Q ) (17) plus the introduction of C65S to avoid potential reactivity with the thiolated DNA. Hence, IN P retains 3 cysteines: C130 and C40 and C43 of the zinc finger. Two clusters of mutant sites were chosen (Fig. 1A) . Cluster 1 (D167C, Q164C, K160C, and L68C) is near K159, a residue previously shown to interact with the conserved 3Ј-A of the penultimate CA dinucleotide (underlined in Fig. 1B) in the viral DNA (19) , and also near the catalytic triad (D64, D116, E152) (20) . Cluster 2 (N117C, G118C, G140C, Y143C, and Q148C) is associated with a flexible loop that contributes to the IN active site (21) . None of the 9 single-cysteine mutations significantly affected protein expression or the solubility of full-length or truncated IN P constructs. All of those tested, including IN Q , the starting quadruple mutant, retained 64-90% WT activity for single-end strand transfer (Fig. S1 ).
To identify and isolate cross-linked complexes, each of the mutant proteins was incubated with 18/20 3Ј-processed DNA thiolated at the 5Ј terminal adenine of the complementary strand of the conserved 3Ј-A (Fig. 1B) (Fig. 1D) , suggesting that D167C, L68C, and C65 are beyond the optimal reach of the 5Ј-terminal thiol group when DNA binds IN. All cluster 2 mutations (N117C, G118C, G140C, Y143C, and Q148C) readily formed IN P -DNA complexes with Ϸ50% of the monomers bound to DNA (Fig. 1D) , consistent with the notion that the loop is flexible (21) and is intimately associated with 3Ј-processed viral DNA bound in the IN active site. determined the ability of IN P K160C , IN P Q164C , and IN P Y143C to bind unprocessed, blunt-ended, thiolated DNA substrates that mimic the true end-product of reverse transcription. Only IN P Y143C crosslinked with blunt-end DNA (Fig. 3A) , suggesting that the flexible loop can maintain contact with the viral DNA during the proposed IN conformational change between the 3Ј-processing and strand transfer steps (6, 7, 12, 21) , and residues K160 and Q164 come into close proximity with the viral end only during the strand transfer step.
To test the hypothesis that DNA binding triggers rearrangement of IN monomers within the DNA-bound IN oligomer, lysines in full-length IN P Y143C and IN P Y143C -DNA complexes were crosslinked by using homo-bifunctional cross-linking reagents with 2 different lengths of spacer arm, disuccinimidyl tartarate (DST) (6.4 Å) and bis(sulfosuccinimidyl)suberate (BS 3 ) (11.4 Å). Whereas the IN P Y143C -DNA complex yielded tetramers and higher-order oligomers when cross-linked using both short (DST) and long (BS 3 ) spacer arms (Fig. 3B , lanes 7 and 8), apo IN P formed tetramers and higher-order oligomers only when using the longer spacer arm (Fig.  3B , lane 3 vs. lane 4). The cross-linked apo IN P and IN P -DNA species migrated predominantly with molecular masses of Ϸ111 Ϯ 7.7 and Ϸ126 Ϯ 2.3 kDa, respectively (Fig. 3B) . The difference is consistent with the addition of 2 DNA molecules (Ϸ7 kDa each for 18/20 DNA as observed on SDS/PAGE gels) to each tetramer. Higher-order oligomers of Ϸ197 kDa for IN P , and Ϸ239 kDa for IN P -DNA, possibly octamers (Fig. 3C) , were also visible. The electrophoretic mobility of Lys-cross-linked IN and Lys-crosslinked IN-DNA was slightly faster than expected relative to the noncross-linked species and the calculated molecular masses (Fig.  3C) , a phenomenon that has been attributed to conformational constraints imposed by Lys cross-linking (11) .
To further probe the conformational changes upon IN-DNA complex formation, we tested protease and nuclease protection (Fig. S2) . Trypsin digestion of IN P Y143C/52-288 (CCD plus CTD) yielded a small amount of a 16-kDa protease-resistant fragment (molecular mass determined by MALDI-TOF MS and SDS/ PAGE). In contrast, trypsin digestion of the IN P Y143C/52-288 -DNA complex yielded a much larger amount of a Ϸ20-kDa protease-resistant fragment. DTT treatment of the Ϸ20-kDa IN P Y143C/52-288 -DNA fragment yielded a 16-kDa protein fragment that comigrates with the fragment from apo-IN. N-terminal sequencing of the 16-kDa protease-resistant fragment showed its amino terminus to be the same as that of the N terminus of IN P Y143C/52-288 . Based on fragment size, the cleavage site is predicted to be within the flexible loop near residue R187 (Fig. 1 A) .
We also probed the nuclease resistance of the bound 18/20 substrate DNA. DNaseI digestion of the IN P Y143C/52-288 -DNA protease-resistant Ϸ20-kDa fragment yielded a complex whose electrophoretic mobility suggests that Ϸ10 bp of IN-bound DNA is highly protected (Fig. S2 ). Proteolytic and nuclease protection was maintained under a variety of different salt, inhibitor, or purification conditions.
DNA Tethering Overcomes IN Requirement of the NTD for Strand
Transfer. Lack of either the NTD or CTD of IN severely impairs strand transfer activity (5, 22) . As expected, the truncated variants IN P K160C/52-288 and IN P Y143C/52-288 demonstrate very low strand transfer activity (Fig. 4) . When donor DNA was cross-linked to these truncated mutants, strand transfer activity was increased by Ϸ5-and 10-fold, respectively (Fig. 4) . The Ϸ40% lower strand transfer activity of cross-linked IN P K160C/52-288 -DNA relative to (Fig. 4) , we sought to ask whether it would bind currently used drugs that are reportedly inhibitors of strand transfer. We therefore validated a scintillation proximity assay (SPA) for measuring the affinity of a known strand transfer inhibitor, [benzene-2- 
Discussion
We describe a functional complex of HIV-1 IN (IN P Y143C ) covalently linked to a short dsDNA that matches the end of the viral DNA. The complex is able to catalyze single-end strand transfer reactions and binds to a strand transfer inhibitor only after complex formation. This complex can help define the basis of substrate binding and may therefore assist in the development of therapeutic inhibitors of IN-mediated integration.
Dynamic Nature of the IN-DNA Complex. Three of our observations support the previously-reported conformational change upon DNA binding and 3Ј processing (6, 7, 12, 21) . First, of the 3 mutants assayed for their ability to bind both blunt-ended and 3Ј-processed DNA, Q164C and K160C effectively bound only the 3Ј-processed DNA, suggesting that the orientation between IN and the DNA substrate differs for the 2 substrates. Second, IN and IN-DNA complexes in solution showed distinct differences in the ability of homo-bifunctional Lys cross-linkers to cross-link IN molecules within soluble oligomeric complexes. Specifically, with DNA bound, monomers of IN can be cross-linked by using shorter (6.4 Å) linker arms, demonstrating different interactions among IN molecules depending on whether they are engaged with DNA and suggesting that DNA binding induces some reorganization of the oligomer that brings lysine sites closer to each other as detected by cross-linking of IN protomers. Third, 3Ј-processed DNA binding induces changes that significantly protect a subdomain (residues 52-187) of the IN CCD from proteolysis.
Upon formation of the IN-DNA complex, the CCD of IN P also protects the bound DNA (Ϸ10 bp) from nuclease action. This result is consistent with the finding of others that IN binds to the 10 terminal base pairs of the viral DNA (24) that influence the efficiency of integration (11) . Ten base pairs is approximately half of the DNA length protected by the full-length IN oligomer in previously-reported stable IN-DNA complexes (11, 25) . From a biological perspective, having IN protect the viral DNA ends from nucleases strategically ensures the integrity of the viral ends, which are essential for viral integration and, thereby, for viral propagation. (Fig. 1C, lanes 3 and 4) . This 2:1 ratio pertains even when DNA was present in molar excess, suggesting that only 1 of the 2 DNA binding pockets in an IN dimer readily binds a viral DNA end. The 2:1 ratio is consistent with the findings of numerous studies including cross-linking (4, 6), complementation (5), fluorescence anisotropy (8, 9) , and small-angle X-ray scattering (7), each of which indicate that a dimer of IN binds a single viral end and is sufficient for 3Ј processing and half-site integration. The (CCD ϩ CTD) IN P K160C/52-288 -DNA complex, which only formed dimers and was unable to form tetramers (Fig.  S3B) , was capable of catalyzing half-site integration (Fig. 4) .
The 2 IN active sites lie on opposite sides of the IN dimer (17, 18, 26) such that DNA binding to 1 active site would not occlude the other site from binding a second DNA. However, there is evidence that binding of viral DNA to only 1 face of the dimer induces asymmetry in the dimer, detected by a decrease in exposure of Arg-199 (located in the linking helix between CCD and CTD) of the DNA-bound monomer, and an increase in exposure of Arg-199 on the other, relative to unbound IN dimers (15) . The asymmetry could therefore be the basis for inactivating the other monomer in the dimer and formation of a so-called tetramer by dimerization of the heterodimer. IN dimers (4) . Second, small peptides have been described that inhibit DNA binding to IN by shifting the IN oligomerization equilibrium from an active dimer toward an inactive tetramer (9) . Third, DNA binding induces dissociation of the multimeric IN (27) . Taken together, these observations suggest that a tetrameric form of the apo IN must dissociate to bind DNA and then reorganize into a tetrameric IN-DNA complex. Consistent with this hypothesis, we find that upon DNA binding to IN P , a higher-order oligomer of Ϸ197 kDa (Fig. 3B, lane 4) is replaced with a lesser amount of distinctly different oligomers, one corresponding to a DNA-bound oligomer of Ϸ239 kDa (Fig. 3B, lane 8) and the other to a DNA-induced dimeric IN P -DNA of Ϸ64 kDa (Fig. 3B, lanes 4 vs. lane 8) . Interestingly, our data show that tetramer formation does not require the NTD as indicated by the ability of the IN P Y143C/52-288 -DNA to form tetramers. We propose that only after the viral DNA has undergone 3Ј processing by an IN dimer does the dimer complex assume the conformation required for interaction with a second IN-DNA dimer of similar conformation, which is required to form the tetramer complex essential for concerted integration. Such a specific sequence of events required to generate IN-DNA tetramers may have biological implications for the retroviral life cycle by preventing unwanted single-ended integration events that could be a dead end for the replicating virus. Sequential reorganization of the IN-DNA complex has been suggested to channel the integration reaction along the correct pathway toward concerted integration (11).
The IN-DNA Dimer. There are 2 possible modes of viral DNA binding within active IN tetramers consistent with current models. In 1 mode, the strand with the 3Ј end that undergoes 3Ј processing would bind to an active site from 1 dimer, while the other strand is somehow unwound from the helix such that the complementary 5Ј end binds to another active site in a second dimer in trans (28) (29) (30) (31) . In the second mode, the complementary 5Ј and 3Ј ends remain double-stranded and bind to a single active site of a single dimer (15) . Our observed half-site integration activity of the cross-linked IN P K160C/52-288 -DNA, cross-linked to DNA through its 5Ј end, which is essentially all dimer as assayed by size exclusion chromatography and MALLS, requires that the 3Ј end also be in the active site of the same monomer. With the slight caveat that possible transient tetramers of IN P K160C/52-288 , although undetected, might carry out the observed half-site integration, our results support the case that each end of the viral DNA duplex (with its 3Ј and complementary 5Ј end) bind to 1 active site of a dimer.
A plausible model for the IN dimer bound to 1 DNA duplex, in which the viral DNA is stabilized by interactions to the CTD and NTD and its 3Ј-CA bound to the CCD of the same dimer, has been described (15) . The model illustrates how the 5Ј-thiol group of the modified DNA is in close proximity to and may cross-link to either K160C or Y143C while at the same time the 3Ј end of the DNA remains at the active site (Fig. 6) . The length of the 6-carbon thiol linker (Ϸ9 Å), the flexibility of the DNA 5Ј overhang, the flexibility of the active site loop (Y143C) that may swing nearly 14 Å (21), and the conformational changes in the DNA and IN upon association are expected to allow the thiol group access to either of the cysteines.
The Drug Binding Pocket. Viral DNA 3Ј end processing by IN is proposed to create a hydrophobic drug binding pocket in the space vacated by the removal of 3Ј-GT, bounded by the flexible active site loop (30) and the 5Ј-CA overhang of the viral DNA (32) . Inhibitor binding is attenuated when either the flexibility of the active site loop is impaired (33) or the 5Ј-CA overhang of the viral DNA is deleted (32) . Although the thiol group on the 5Ј-CA overhang cross-links efficiently to either K160C or Y143C, only cross-linked Y143C binds IN inhibitor. We suggest that 5Ј cross-linking to Y143C retains enough flexibility to allow formation of the natural binding pocket that is bounded by the 5Ј-CA overhang and active site loop, whereas 5Ј-CA cross-linking to K160C constrains the 5Ј-CA overhang from moving toward the inhibitor to contribute to the binding pocket. Although 5Ј-CA cross-linking to K160C attenuates drug binding, it does not seem to affect the position of the 3Ј end in the catalytic site as indicated by strand transfer activity of IN P K160C/52-288 -DNA. The cross-linking data presented add to the repertoire of IN-DNA modeling constraints, which have so far been insufficient to generate a unified model.
In conclusion, we harnessed a series of IN cysteine mutations and selective reducing conditions to identify a stable IN-DNA complex, IN P Y143C -DNA, that retains its ability to catalyze half-site integration and contains a binding site for a validated strand transfer inhibitor. This complex can serve as a platform for structural analysis and optimization of drug candidates that target integration of HIV.
Experimental Procedures
Mutagenesis. Mutations C56S, W131D, F185D, and C280S were introduced into a synthetic full-length HIV-1 IN (SF1), termed INQ (Quadra mutant), and cloned into pt7-7 (17). We removed an additional native cysteine, C65, to generate IN C56S/W131D/ F185D/C280S/C65S , termed INP (Penta mutant). An N-terminal 6-histidine (6-His) tag followed by a thrombin cleavage site (Stratagene) was added for purification. INP 52-210 , INP , and INP 52-288 , were generated from INP . Additional cysteine mutations were introduced by site-directed mutagenesis using the QuikChange Kit (Stratagene). All constructs were confirmed by DNA sequencing. Oligodeoxynucleotides. The thiol group was located at the end of a 6-carbon linker attached to a phosphate at the 5Ј end of the oligonucleotide (5Ј-Xactgctagagattttccaca-3Ј [X: 5Ј-C6 Thiol linker]) (TriLink). Complementary sequences of either 18 bp (5Ј-tgtggaaaatctctagca-3Ј) or 20 bp (5Ј-tgtggaaaatctctagcagt-3Ј) were annealed by slow cooling after 3 min at 95°C. After deprotection and activation (40 mM DTT, 170 mM phosphate buffer, pH 8.0, at 37°C for 16 h), the thiolated dsDNAs were desalted by using G-25 Microspin columns (GE Healthcare Bio-Sciences) and treated with 1 mM 5,5Ј-dithio-bis(2-nitrobenzoic acid) (DTNB) (Sigma) at room temperature for 1 h (6), followed by a second desalting. (30) . Model of viral DNA bound to IN dimer has been described (15) , and coordinates were generously obtained from M. Kvaratskhelia (Ohio State University, Columbus, OH). Loop coordinates were obtained from the CCD structure (1BI4) (16) . The figure was made with Pymol (DeLano Scientific).
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